scispace - formally typeset
R

Raffaella Origa

Researcher at University of Cagliari

Publications -  98
Citations -  3993

Raffaella Origa is an academic researcher from University of Cagliari. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 25, co-authored 85 publications receiving 3406 citations.

Papers
More filters
Journal ArticleDOI

Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.

TL;DR: This dissertation aims to provide a history of Hematology/Medical Oncology at the cellular level and investigates the role of “blank-label” chemotherapy in the development of certain types of cancer.
Journal ArticleDOI

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

TL;DR: This retrospective study assessed long-term renal safety of deferasirox in Italian pts with transfusional hemosiderosis who participated in the defer asirox registration studies and continued treatment for up to 10 or more yrs, and found mean SCr and UPCR values were within normal limits and stable over time during the retrospective period.
Journal ArticleDOI

Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)

TL;DR: Treatment adherence is crucial for optimizing long-term iron chelation therapy (ICT) in this patient, which depends on the mode of administration, frequency of dosing, palatability, and the adverse event (AE) profile of ICT.
Journal ArticleDOI

Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies

TL;DR: Good Practice Recommendations are the final outcome of translational research and allow one to transfer to the daily clinical practice of endocrine complications in haemoglobinopathies.
Journal ArticleDOI

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence

TL;DR: In this article , the authors developed a set of questions for the practical management of luspatercept in the treatment of beta-thalassemia, which was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies.